HP560 / Hinova Pharma - LARVOL DELTA

Haichuang Pharmaceutical Co., Ltd. voluntarily discloses the announcement on the approval of clinical trial of HP560 tablets for the treatment of myelofibrosis (myeloproliferative neoplasms) [Google translation] (Sina Corp) - "Recently, Haichuang Pharmaceutical Co., Ltd...received the 'Drug Clinical Trial Approval Notice' approved and issued by the Drug Evaluation Center of the China National Drug Administration, agreeing to conduct clinical trials of HP560 tablets for the treatment of myelofibrosis. Upon inquiry, as of the date of disclosure of this announcement, no similar target products have been approved for marketing at home and abroad."

New trial • Hematological Malignancies • Myelofibrosis • Myeloproliferative Neoplasm • Oncology

Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis (AACR 2024) - "HP560 has high binding affinities for all BET proteins and strong anti-proliferative activity as well as synergistic anti-proliferative effect in combination with ruxolitinib, a JAK1/2 inhibitor. Together, HP560 is a potent pan-BET inhibitor and can be developed as a monotherapy or in combination with a JAK inhibitor for the treatment of MF. HP560 structure will not be disclosed."

Late-breaking abstract • Acute Myelogenous Leukemia • Leukemia • Myelofibrosis • Oncology